



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Kalla et al

Confirmation No.: 1946

Serial No.: 10/719,102

Group Art Unit: 1624

Filing Date: November 21, 2003

Examiner: Not Assigned

Title: A_{2B} Adenosine Receptor Antagonists

INFORMATION DISCLOSURE STATEMENT

Mail Stop IDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration.

Applicants respectfully request that the Examiner review and make of record the references identified below.

The references identified below and listed on the attached PTO-1449 form as Reference Nos. 1-7 were disclosed and/or cited in parent application Serial No. 10/431,167, filed May 6, 2003. As such, copies of the references are not included pursuant to the provisions of 37 CFR § 1.98(d).

U.S. PATENT DOCUMENTS		
Document No.	Issue Date or Publication Date	Name of Patentee or Applicant
4,452,788	June 5, 1984	Bristol et al
4,879,296	November 7, 1989	Daluge et al
4,558,051	December 10, 1985	Sunshine et al
4,593,095	June 3, 1986	Snyder et al
4,879,296	November 7, 1989	Daluge et al
5,532,368	July 2, 1996	Kufner-Muhl et al
5,641,784	June 24, 1997	Kufner-Muhl et al
5,714,494	February 3, 1998	Connell et al
6,060,481	May 9, 2000	La Noue et al
6,117,878	September 12, 2000	Linden
6,437,124	August 20, 2002	Daluge et al
6,545,002	April 8, 2003	Linden et al

FOREIGN PATENT DOCUMENTS		
Document No.	Publication Date	Country
EP 0386683	September 12, 1990	EP
EP 0986855	November 17, 1999	EP
EP 1084710	March 21, 2001	EP
WO 9942093	August 26, 1999	WIPO
WO 0009507	February 24, 2000	WIPO
WO 9511681	May 4, 1995	WIPO
WO 0073307	December 7, 2000	WIPO

NONPATENT DOCUMENTS
JACOBSON K A et al: "1,3-Dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors", Drug Development Research, New York, NY, US, vol. 47, no. 1, 1999, pages 45-53, XP000942540, abstract; example 10D
KUZ' MENKO I I et al, "Reactions of Theophyllines, Chemical Conversions of 8-Aminotheophyllinates" Chemistry of Heterocyclic Compounds (A translation of Khimiya Geterotsiklicheskikh Soedinenii), Plenum Press Co., New York NY, US, vol. 36, no. 8, 2000 pages 963-970 XP001146936 ISSN: 0009-3122 examples 3K,3L,8

As the subject application was filed after June 30, 2003, copies of the U.S. patents and/or publications disclosed above are not required and, therefore, are not included.


Applicants would appreciate the Examiner's initialing and returning the attached PTO-1449 form to indicate that all the references identified herein have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 50-1789 may be charged therefor.

Respectfully submitted,


By:



Brian Lewis
Registration No. 32,502

CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, California 94304
(650) 384-8500 Telephone
(650) 475-0359 Facsimile

S:\LEGALCVT\Patent\Forms\IDS - Before 1st OA with Parent & New References.DOC



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/719,102
Filing Date	November 21, 2003
First Named Inventor	Rao Kalla
Art Unit	1624
Examiner Name	
Attorney Docket Number	01-163-CIP2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
	1	4,452,788	June 5, 1984	Bristol et al			
	2	4,879,296	November 7, 1989	Daluge et al			
	3	4,558,051	December 10, 1985	Sunshine et al			
	4	4,593,095	June 3, 1986	Snyder et al			
	5	4,879,296	November 7, 1989	Daluge et al			
	6	5,532,368	July 2, 1996	Kufner-Muhl et al			
	7	5,641,784	June 24, 1997	Kufner-Muhl et al			
	8	5,714,494	February 3, 1998	Connell et al			
	9	6,060,481	May 9, 2000	La Noue et al			
	10	6,117,878	September 12, 2000	Linden			
	11	6,437,124	August 20, 2002	Daluge et al			
	12	6,545,002	April 8, 2003	Linden et al			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
	13	EP 0386683	September 12, 1990	EP			
	14	EP 0986855	November 17, 1999	EP			
	15	EP 1084710	March 21, 2001	EP			
	16	WO 9942093	August 26, 1999	WIPO			
	17	WO 0009507	February 24, 2000	WIPO			
	18	WO 9511681	May 4, 1995	WIPO			
	19	WO 0073307	December 7, 2000	WIPO			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	20	JACOBSON K A et al: "1,3-Dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors", Drug Development Research, New York, NY, US, vol. 47, no. 1, 1999, pages 45-53, XP000942540, abstract; example 10D	
	21	KUZ' MENKO I I et al, "Reactions of Theophyllines, Chemical Conversions of 8-Aminothetheophyllinates" Chemistry of Heterocyclic Compounds (A translation of Khimiya Geterotsiklicheskikh Soedinenii), Plenum Press Co., New York NY, US, vol. 36, no. 8, 2000 pages 963-970 XP001146936 ISSN: 0009-3122 examples 3K,3L,8	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.